Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

• Citi's 18th Annual BioPharma Conference
  Date: Wednesday, September 6, 2023
  Location: Boston, MA
  Format: 1x1 Meetings

• Morgan Stanley 21st Annual Global Healthcare Conference
  Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time
  Location: New York, NY
  Format: Fireside Chat and 1x1 Meetings

• TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
  Date/Time: Wednesday, September 20, 2023 at 5:00 p.m. Eastern Time
  Location: Virtual
  Format: Fireside Chat

• Cantor Fitzgerald Global Healthcare Conference
  Date/Time: Tuesday, September 26, 2023 at 11:30 a.m. Eastern Time
  Location: New York, NY
  Format: Fireside Chat and 1x1 Meetings

Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. 

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230823759521/en/

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
[email protected]

Investor Contact:
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
[email protected]

Source: Acadia Pharmaceuticals Inc.

You May Also Be Interested In

• Norton Manx R Earns Landmark International Design Excellence Award for Reimagining the Superbike
• From Whitelist to the Next Meme Wave: Apeing Eyes the Best Meme Coin Spot While Snek and Pepe Hold Their Ground
• 40 Acres And A Profit Launches The Levi Bean Lake Real Estate Course Built on Real Houses and $1M+ in Capital